$NGNE
Neurogene Inc.

2015 Q1 Form 10-K Financial Statement

#000119312515093873 Filed on March 16, 2015

View on sec.gov

Income Statement

Concept 2015 Q1 2014 Q4 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.470M $1.490M $740.0K
YoY Change 98.65% 115.94% 76.19%
% of Gross Profit
Research & Development $4.567M $6.330M $1.880M
YoY Change 142.93% 130.18% 228.12%
% of Gross Profit
Depreciation & Amortization $18.24K
YoY Change 23.35%
% of Gross Profit
Operating Expenses $6.039M $7.820M $2.615M
YoY Change 130.94% 127.33% 162.33%
Operating Profit
YoY Change
Interest Expense $6.000K -$10.00K $454.0K
YoY Change -98.68% -80.0% 24654.63%
% of Operating Profit
Other Income/Expense, Net -$373.0K -$260.0K -$1.613M
YoY Change -76.88% 420.0% 11905.95%
Pretax Income -$6.412M -$8.090M -$4.228M
YoY Change 51.66% 128.53% 318.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.412M -$8.090M -$4.228M
YoY Change 51.66% 128.53% 318.5%
Net Earnings / Revenue
Basic Earnings Per Share -$1.28
Diluted Earnings Per Share -$598.5K -$754.7K -$1.28
COMMON SHARES
Basic Shares Outstanding 10.72M shares 10.70M shares 3.148M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2015 Q1 2014 Q4 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.40M $39.10M $55.60M
YoY Change -38.13% 183.33%
Cash & Equivalents $14.28M $14.91M $52.92M
Short-Term Investments $20.10M $24.20M $2.700M
Other Short-Term Assets $500.0K $100.0K $500.0K
YoY Change 0.0% -93.33%
Inventory
Prepaid Expenses $547.8K
Receivables $100.0K $100.0K $100.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $35.02M $39.30M $56.25M
YoY Change -37.74% 156.93%
LONG-TERM ASSETS
Property, Plant & Equipment $97.00K $105.0K $67.38K
YoY Change 43.96% 39.14%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $2.000M
YoY Change
Other Assets $12.00K $13.00K $135.3K
YoY Change -91.13% -95.31%
Total Long-Term Assets $109.0K $2.121M $202.7K
YoY Change -46.23% 501.27%
TOTAL ASSETS
Total Short-Term Assets $35.02M $39.30M $56.25M
Total Long-Term Assets $109.0K $2.121M $202.7K
Total Assets $35.13M $41.42M $56.45M
YoY Change -37.77% 164.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.000M $5.200M $1.200M
YoY Change 316.67% 766.67%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $4.972M $5.203M $1.238M
YoY Change 301.74% 98.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $100.0K $72.00K $7.047K
YoY Change 1319.04% 741.12%
Total Long-Term Liabilities $100.0K $72.00K $7.047K
YoY Change 1319.04% 741.12%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.972M $5.203M $1.238M
Total Long-Term Liabilities $100.0K $72.00K $7.047K
Total Liabilities $5.051M $5.275M $1.352M
YoY Change 273.53% -29.52%
SHAREHOLDERS EQUITY
Retained Earnings -$95.83M -$89.42M
YoY Change 36.11%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $30.08M $36.15M -$65.39M
YoY Change
Total Liabilities & Shareholders Equity $35.13M $41.42M $56.45M
YoY Change -37.77% 164.69%

Cashflow Statement

Concept 2015 Q1 2014 Q4 2014 Q1
OPERATING ACTIVITIES
Net Income -$6.412M -$8.090M -$4.228M
YoY Change 51.66% 128.53% 318.5%
Depreciation, Depletion And Amortization $18.24K
YoY Change 23.35%
Cash From Operating Activities -$6.300M -$6.700M -$3.800M
YoY Change 65.79% 79.14% 322.22%
INVESTING ACTIVITIES
Capital Expenditures $6.000K -$20.00K $4.000K
YoY Change 50.0% -14.82%
Acquisitions
YoY Change
Other Investing Activities $6.070M $6.080M $0.00
YoY Change -316.37% -100.0%
Cash From Investing Activities $6.060M $6.050M $0.00
YoY Change -315.3% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 70.00K 0.000 45.72M
YoY Change -99.85% -100.0% 155.85%
NET CHANGE
Cash From Operating Activities -6.300M -6.700M -3.800M
Cash From Investing Activities 6.060M 6.050M 0.000
Cash From Financing Activities 70.00K 0.000 45.72M
Net Change In Cash -170.0K -650.0K 41.92M
YoY Change -100.41% -86.32% 146.3%
FREE CASH FLOW
Cash From Operating Activities -$6.300M -$6.700M -$3.800M
Capital Expenditures $6.000K -$20.00K $4.000K
Free Cash Flow -$6.306M -$6.680M -$3.804M
YoY Change 65.77% 78.61% 320.47%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
11.00
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
-65388547
CY2013Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
412038
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2014Q1 aqxp Stock Shares Authorized Net
StockSharesAuthorizedNet
55000000 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10717128 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
41572146
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-39314581
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9239188
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-51101207
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2000539
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
301745 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
301745 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
139266037 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.83
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
736333 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
628754 shares
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
73858722
CY2013Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
19445
CY2013Q4 us-gaap Loans Payable To Bank Current
LoansPayableToBankCurrent
250000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
16094141
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
252729
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Long Term Loans From Bank
LongTermLoansFromBank
2036489
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2620105
CY2013Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
221320
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-65693708
CY2013Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
1797412
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2350660
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-65693708
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8560
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
47742
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15649106
CY2013Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
1797412
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
890248
CY2013Q4 us-gaap Line Of Credit
LineOfCredit
2286489
CY2013Q4 us-gaap Liabilities
Liabilities
7484092
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
247667
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
599833
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11006392
CY2013Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
1799074
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
75465
CY2013Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
27946
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
122066
CY2013Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3714276
CY2013Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
1377438
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
477682
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
10560895
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
328194
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
2820600
CY2013Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4933498
CY2013Q4 us-gaap Assets
Assets
15649106
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2013Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
2820600
CY2013Q4 us-gaap Cash
Cash
7292116
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
277290
CY2013Q4 us-gaap Assets Current
AssetsCurrent
15296351
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
2820600
CY2013Q4 aqxp Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
565170
CY2013Q4 aqxp Derivative Liabilities Noncurrent Redemption Option
DerivativeLiabilitiesNoncurrentRedemptionOption
800206
CY2013Q4 aqxp Prepayments And Deposits Current
PrepaymentsAndDepositsCurrent
63975
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
10695108 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10695108 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.79
CY2014Q4 us-gaap Minority Interest Ownership Percentage By Parent
MinorityInterestOwnershipPercentageByParent
1.00 pure
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
429369 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
6.79
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.000001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.000001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
598812 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20613837
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
277867
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5203308
CY2014Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
72341
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
11
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3855
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89415563
CY2014Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
0
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
5203308
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
36147298
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
87519
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
217296
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four And Five Years
OperatingLeasesFutureMinimumPaymentsDueInFourAndFiveYears
0
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
41422947
CY2014Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125566705
CY2014Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
0
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
247471
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two And Three Years
OperatingLeasesFutureMinimumPaymentsDueInTwoAndThreeYears
45270
CY2014Q4 us-gaap Liabilities
Liabilities
5275649
CY2014Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
382254
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
734192
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
172026
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14906087
CY2014Q4 us-gaap Fair Value Net Asset Liability
FairValueNetAssetLiability
26121977
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
104694
CY2014Q4 us-gaap Available For Sale Securities Noncurrent
AvailableForSaleSecuritiesNoncurrent
2003099
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0211 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301745 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2014Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
65447
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
404810
CY2014Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
6555202
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
1403318
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
13858491
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
382561
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
646363
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
24195303
CY2014Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
4947218
CY2014Q4 us-gaap Assets
Assets
41422947
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2643323
CY2014Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
24191219
CY2014Q4 us-gaap Cash
Cash
8350885
CY2014Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
13395
CY2014Q4 us-gaap Assets Current
AssetsCurrent
39301759
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
24191219
CY2014Q4 aqxp Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingAggregateIntrinsicValue
788840
CY2014Q4 aqxp Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
3751872
CY2014Q4 aqxp Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
2002870
CY2014Q4 aqxp Share Based Compensation Arrangement By Share Based Payment Award Number Of Options Outstanding
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfOptionsOutstanding
824604 shares
CY2014Q4 aqxp Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
2003099
CY2014Q4 aqxp Prepayments And Deposits Current
PrepaymentsAndDepositsCurrent
139006
CY2014Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.052083 pure
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4830000 shares
CY2014Q1 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
5838726
CY2014Q1 aqxp Net Proceeds From Issuance Initial Public Offering
NetProceedsFromIssuanceInitialPublicOffering
47291274
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
77333851
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
47291278
us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
5838726
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3855
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
460
us-gaap Stock Issued During Period Value Issued For Noncash Considerations
StockIssuedDuringPeriodValueIssuedForNoncashConsiderations
186356
us-gaap Net Income Loss
NetIncomeLoss
-24027016
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
754771
CY2013Q1 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2013-12-23
CY2013Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
3393
CY2013Q1 aqxp Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
415431
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.40
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7938014
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
108942
CY2013 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
961641
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
587438
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
11741
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-14941829
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-8729371
CY2013 us-gaap Interest Paid
InterestPaid
22604
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
349321
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
147282
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-49.52
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.94 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6183632 shares
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
223910
CY2013 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
2820600
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-8881697
CY2013 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
107622
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
102792
CY2013 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-599
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8734415
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
134553
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8729371
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
641240
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-8734415
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
349321
CY2013 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
59571
CY2013 us-gaap Interest Expense
InterestExpense
42923
CY2013 us-gaap Operating Expenses
OperatingExpenses
9375655
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7598750
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
14242
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
9005853
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5044
CY2013 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
123074
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
19584391
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
191817
CY2013 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
93663
CY2013 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-363706
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-2640524
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1776905
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1180190
CY2013 us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
2500000
CY2013 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
18003361
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
349321
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
2500412
CY2013 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
26316
CY2013 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
2500000
CY2013 aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
386420
CY2013 aqxp Discount On Issuance Of Warrants
DiscountOnIssuanceOfWarrants
226255
CY2013 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
737925
CY2013 aqxp Share Issuance Expenditures Incurred But Not Yet Paid
ShareIssuanceExpendituresIncurredButNotYetPaid
790000
CY2013 aqxp Fair Value Transfers Between Level One Level Two And Level Three Amount
FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount
0
CY2013 aqxp Accretion Of Warrant Discount1
AccretionOfWarrantDiscount1
12744
CY2013 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Amount
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedAmount
-2235488
CY2013 aqxp Income Tax Reconciliation Other Impact Upon Conversion Of Taxable Preferred Stock Amount
IncomeTaxReconciliationOtherImpactUponConversionOfTaxablePreferredStockAmount
5119
CY2013 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Percent
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedPercent
0.256 pure
CY2013 aqxp Adjustments For Temporary Equity Accretion Liquidation Preference
AdjustmentsForTemporaryEquityAccretionLiquidationPreference
5351459
CY2013 aqxp Adjustments To Additional Paid In Capital Temporary Equity Stock Issued During Period
AdjustmentsToAdditionalPaidInCapitalTemporaryEquityStockIssuedDuringPeriod
7
CY2013 aqxp Effective Income Tax Rate Reconciliation Tax Expense Credit Investment Amount
EffectiveIncomeTaxRateReconciliationTaxExpenseCreditInvestmentAmount
-5044
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
CY2014 dei Entity Registrant Name
EntityRegistrantName
AQUINOX PHARMACEUTICALS, INC
CY2014 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company currently files income tax returns in the United States and Canada, the jurisdictions in which the Company believes that it is subject to tax. Further, while the statute of limitations in each jurisdiction where an income tax return has been filed generally limits the examination period, as a result of loss carry-forwards, the limitation period for examination generally does not expire until several years after the loss carry-forwards are utilized. Other than routine audits by tax authorities for tax credits and tax refunds that the Company has claimed, management is not aware of any other material income tax examination currently in progress by any taxing jurisdiction.
CY2014 us-gaap Concentration Risk Patent And Other Rights
ConcentrationRiskPatentAndOtherRights
The agreement expires at the earlier of the last expiry of any patent obtained related to the technology or through enactment of one of the termination clauses stipulated in the agreement.
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
229082 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.76
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
AQXP
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
The Company effected a 1-for-19.2 reverse stock split
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.19
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.26 pure
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y11M9D
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b>1. Nature of operations</b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals, Inc. and its wholly owned subsidiary, Aquinox Pharmaceuticals (Canada) Inc., (consolidated and combined the &#x201C;Company&#x201D;&#x2014;see Note&#xA0;2 Basis of presentation) is a clinical stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox Pharmaceuticals (USA) Inc. was incorporated on May&#xA0;31, 2007 in the State of Delaware, United States. On January&#xA0;27, 2014, Aquinox Pharmaceuticals (USA) Inc. changed its name to Aquinox Pharmaceuticals, Inc. (&#x201C;Aquinox USA&#x201D;).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Aquinox Pharmaceuticals (Canada) Inc. (&#x201C;AQXP Canada&#x201D;), was originally incorporated under the name of 6175813 Canada Inc. on December&#xA0;26, 2003 under the Canada Business Corporations Act. In May 2014, after a corporate restructuring, the name was changed to Aquinox Pharmaceuticals (Canada) Inc.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> The Company operates in Vancouver, British Columbia, Canada.</p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17805565
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2014 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.052083 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0167 pure
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(d) Use of estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant areas requiring management estimates include whether the use of the going concern assumption is appropriate, valuation of stock options and warrants, amortization and depreciation, accrual of expenses, valuation allowance for deferred income taxes, and contingencies. Actual results could differ from those estimates.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8667387 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
5.98
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y1M28D
CY2014 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-20235
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y6M29D
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
33146 shares
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
10.13
CY2014 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
37502
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-24027238
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
14672
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001404644
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.75
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24030871
CY2014 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1651529
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.08 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
835971 shares
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b><i>(q) Concentration of credit risk</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash and cash equivalents, short-term investments and long-term investments. Cash, cash equivalents and investments are invested in accordance with the Company&#x2019;s investment policy. The primary objective for the Company&#x2019;s investment portfolio is the preservation of capital and maintenance of liquidity and includes guidelines on the quality of financial instruments and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk.</p> </div>
CY2014 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
Less than a 50%
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
86 shares
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
36474883
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-20538640
CY2014 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-107754
CY2014 us-gaap Payments Of Loan Costs
PaymentsOfLoanCosts
100000
CY2014 us-gaap Line Of Credit Facility Increase Accrued Interest
LineOfCreditFacilityIncreaseAccruedInterest
9844
CY2014 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2609844
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-24027238
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-254890
CY2014 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
949185
CY2014 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
20803
CY2014 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5251288
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
113890
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23821276
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-24027016
CY2014 us-gaap Interest Paid
InterestPaid
31719
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3855
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-3488598
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
854188
CY2014 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
135946
CY2014 us-gaap Interest Expense
InterestExpense
461587
CY2014 us-gaap Operating Expenses
OperatingExpenses
22375709
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18079262
CY2014 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
319635
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
3899695
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-222
CY2014 us-gaap Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
186356
CY2014 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
19551
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
45278582
CY2014 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
25894
CY2014 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
185041
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-23573322
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
460
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4296447
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3614459
CY2014 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
53130000
CY2014 us-gaap Proceeds From Repurchase Of Redeemable Preferred Stock
ProceedsFromRepurchaseOfRedeemablePreferredStock
-590
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
12989557
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
854188
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
141
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
4519695
CY2014 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
91327
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
-2500000
CY2014 aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
1884237
CY2014 aqxp Operating Loss Carryforwards Expiration Range
OperatingLossCarryforwardsExpirationRange
2026 through 2034
CY2014 aqxp Percentage Of Recognition Of Tax Benefit Upon Settlement
PercentageOfRecognitionOfTaxBenefitUponSettlement
0.50 pure
CY2014 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
100291
CY2014 aqxp Extinguishment Of Discount On Temporary Equity
ExtinguishmentOfDiscountOnTemporaryEquity
800206
CY2014 aqxp Percentage Threshold For Majority Of Preferred Stock Holders
PercentageThresholdForMajorityOfPreferredStockHolders
0.65 pure
CY2014 aqxp Reversal Of Income Tax Payable On Preferred Stock
ReversalOfIncomeTaxPayableOnPreferredStock
1897702
CY2014 aqxp Liquidation Preference Description
LiquidationPreferenceDescription
The Series C preferred stock is senior to Series A and Series B preferred stock with respect to dividend and redemption rights. In voluntary or involuntary liquidation, dissolution, change of control or winding up of the Company, the Series C preferred stockholders will receive two times the original issue price of the preferred stock, plus 8% per annum of the original issue price compounded annually, and all declared but unpaid dividends on preferred stock. After payment of the Series C preference, the Series A and Series B stockholders will receive the original issue price per share of such series of preferred stock, plus 8% per annum of the original issue price compounded annually, and all declared but unpaid dividends on preferred stock. Assets and funds are then distributed pro rata to preferred stockholders and common stockholders until the holders of preferred stock have received total payments equal to three times the applicable original issue price. Any remaining assets and funds are distributed to the common stockholders.
CY2014 aqxp Convertible Preferred Stock Conversion Price Per Share
ConvertiblePreferredStockConversionPricePerShare
10.56
CY2014 aqxp Accretion Of Warrant Discount
AccretionOfWarrantDiscount
213511
CY2014 aqxp Common Stock Reserved For Issuance Description
CommonStockReservedForIssuanceDescription
Additionally, the number of shares of common stock reserved for issuance under the 2014 Plan will automatically increase on January 1 of each year for a period of up to 10 years, beginning on January 1, 2015 and ending on and including January 1, 2024, by 4% of the total number of shares of capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the board of directors.
CY2014 aqxp Fair Value Transfers Between Level One Level Two And Level Three Amount
FairValueTransfersBetweenLevelOneLevelTwoAndLevelThreeAmount
0
CY2014 aqxp Stock Based Compensation Increase In Common Stock Issuance Percentage
StockBasedCompensationIncreaseInCommonStockIssuancePercentage
0.04 pure
CY2014 aqxp Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock
ExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock
439227
CY2014 aqxp Period Shares Reserved For Issuance Will Increase
PeriodSharesReservedForIssuanceWillIncrease
P10Y
CY2014 aqxp Fee And Penalty On Bank Loan Repayment
FeeAndPenaltyOnBankLoanRepayment
100000
CY2014 aqxp Long Term Investments Maturity Period Maximum
LongTermInvestmentsMaturityPeriodMaximum
P24M
CY2014 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Amount
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedAmount
-6561056
CY2014 aqxp Income Tax Reconciliation Reversal Of Income Tax Related To Taxable Preferred Stock
IncomeTaxReconciliationReversalOfIncomeTaxRelatedToTaxablePreferredStock
1684713
CY2014 aqxp Income Tax Reconciliation Other Impact Upon Conversion Of Taxable Preferred Stock Amount
IncomeTaxReconciliationOtherImpactUponConversionOfTaxablePreferredStockAmount
171607
CY2014 aqxp Redemption Of Preferred Stock Period
RedemptionOfPreferredStockPeriod
P5Y
CY2014 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Percent
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedPercent
0.273 pure
CY2014 aqxp Adjustments For Temporary Equity Accretion Liquidation Preference
AdjustmentsForTemporaryEquityAccretionLiquidationPreference
1132893
CY2014 aqxp Effective Income Tax Rate Reconciliation Tax Expense Credit Investment Amount
EffectiveIncomeTaxRateReconciliationTaxExpenseCreditInvestmentAmount
-222
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.14
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7232202
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0179 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
301745 shares
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-40.23
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.90 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4372889 shares
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-7431876
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
12076
CY2012 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-190645
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7671904
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7714198
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
9114
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-7671904
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64032
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6447
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12137948
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-7714198
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
351322
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-240028
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
351322
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
130784
CY2012 us-gaap Interest Expense
InterestExpense
9470
CY2012 us-gaap Operating Expenses
OperatingExpenses
7681018
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6045395
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7238649
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42294
CY2012 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
168702
CY2012 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
119829
CY2014Q1 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
100291
CY2014Q1 aqxp Adjustments For Temporary Equity Accretion Liquidation Preference
AdjustmentsForTemporaryEquityAccretionLiquidationPreference
1132893
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6447
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1635623
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-224127
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
351322
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1719347
CY2012 aqxp Amortization Of Preferred Stock Discount
AmortizationOfPreferredStockDiscount
45448
CY2014Q1 aqxp Equity Adjustment Extinguishment Of Remaining Share Issuance Costs Due To Conversion Of Preferred Stock
EquityAdjustmentExtinguishmentOfRemainingShareIssuanceCostsDueToConversionOfPreferredStock
1458478
CY2012 aqxp Income Tax Expense On Preferred Stock
IncomeTaxExpenseOnPreferredStock
394908
CY2012 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Amount
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedAmount
-1936264
CY2012 aqxp Income Tax Reconciliation Other Impact Upon Conversion Of Taxable Preferred Stock Amount
IncomeTaxReconciliationOtherImpactUponConversionOfTaxablePreferredStockAmount
97088
CY2012 aqxp Effective Income Tax Rate Reconciliation At Domestic And Foreign Income Tax Rate Combined Percent
EffectiveIncomeTaxRateReconciliationAtDomesticAndForeignIncomeTaxRateCombinedPercent
0.251 pure
CY2012 aqxp Adjustments For Temporary Equity Accretion Liquidation Preference
AdjustmentsForTemporaryEquityAccretionLiquidationPreference
3860140
CY2012 aqxp Effective Income Tax Rate Reconciliation Tax Expense Credit Investment Amount
EffectiveIncomeTaxRateReconciliationTaxExpenseCreditInvestmentAmount
42294
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
99417
CY2014Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
19550

Files In Submission

Name View Source Status
0001193125-15-093873-index-headers.html Edgar Link pending
0001193125-15-093873-index.html Edgar Link pending
0001193125-15-093873.txt Edgar Link pending
0001193125-15-093873-xbrl.zip Edgar Link pending
aqxp-20141231.xml Edgar Link completed
aqxp-20141231.xsd Edgar Link pending
aqxp-20141231_cal.xml Edgar Link unprocessable
aqxp-20141231_def.xml Edgar Link unprocessable
aqxp-20141231_lab.xml Edgar Link unprocessable
aqxp-20141231_pre.xml Edgar Link unprocessable
d851032d10k.htm Edgar Link pending
d851032dex231.htm Edgar Link pending
d851032dex311.htm Edgar Link pending
d851032dex312.htm Edgar Link pending
d851032dex321.htm Edgar Link pending
d851032dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g851032g14u83.jpg Edgar Link pending
g851032g43e93.jpg Edgar Link pending
g851032g59s05.jpg Edgar Link pending
g851032g60a64.jpg Edgar Link pending
g851032g88v51.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending